Alexion Pharmaceuticals, Inc.
NASDAQ: ALXN
$182.50
+$0.00 (+0.0%)
Closing Price on July 28, 2021
ALXN Articles
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
Published:
SunTrust Robinson Humphrey opens up coverage of the biotech sector with four top biotech stocks to buy and one Neutral-rated stock.
Published:
Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.
Published:
Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.
Published:
ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will change...
Published:
ThinkstockFor the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street has loudly stepped up to the plate and advised investors to buy the top biotech...
Published:
In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit the tape.
Published:
A new report from the analysts at Cowen shows that, on average, biotech stocks gained 84% in the 12 months prior to an FDA approval and lost 24% in the 12 months after the approval.
Published:
ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company or sector, or in the case of...
Published:
A new research report from Cowen suggests that biotech investors appear to be looking forward to what they describe as a "return to normalcy" following the roller coaster ride of early 2014.
Published:
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index and...
Published:
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a perfect entry point for...
Published:
Five years ago, many investors had thrown in the towel. The S&P 500 hit an ominous intraday low of 666 and closed at 676.53. The world was coming to an end, and the last place anybody wanted to...
Published:
Last Updated:
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board. Investors who...
Published:
The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility that some of the top names may also become takeover targets this year.
Published: